Trevena Company Profile (NASDAQ:TRVN)

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.19. View Trevena's Earnings History.

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Trevena.

11 analysts have issued 12 month target prices for Trevena's shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Trevena's stock price to reach $11.73 in the next twelve months. View Analyst Ratings for Trevena.

Here are some recent quotes from research analysts about Trevena stock:

• 1. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
• 2. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (3/29/2017)
• 3. Cowen and Company analysts commented, "TRVN reported 4Q16 results." (3/22/2017)
• 4. HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
• 5. Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)

Some companies that are related to Trevena include Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Merus N.V. (MRUS), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), DURECT Corporation (DRRX), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Immune Design Corp. (IMDZ), Circassia Pharmaceuticals PLC (CIR), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), ObsEva SA (OBSV), Pieris Pharmaceuticals (PIRS), Stemline Therapeutics (STML), Chimerix (CMRX), Cempra (CEMP) and OVID THERAPEUTC (OVID).

Trevena's management team includes the folowing people:

• Leon O. Moulder Jr., Independent Chairman of the Board
• Maxine Gowen Ph.D., President, Chief Executive Officer, Director
• Roberto E. Cuca, Chief Financial Officer, Senior Vice President
• Michael W. Lark Ph.D., Senior Vice President - Research, Chief Scientific Officer
• John M. Limongelli Esq., Senior Vice President, General Counsel, Corporate Secretary
• Carrie L. Bourdow, Senior Vice President, Chief Commercial Officer
• Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning
• David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer
• Michael R. Dougherty, Independent Director
• Adam M. Koppel M.D. Ph.D., Independent Director

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Trevena stock can currently be purchased for approximately $2.76.